Carisma Therapeutics Inc (NASDAQ: CARM) is a clinical-stage biopharmaceutical company developing engineered macrophage and monocyte cell therapies for cancer and other serious diseases. The company does not generate product revenue, relying instead on collaboration agreements, grants, and equity financing to fund operations, as disclosed in its 10-K filed 2025-03-31. No product revenue, commercial partnerships with disclosed financials, or named competitors are supported by the excerpts provided.

Revenue model

No product revenue as of the 10-K filed 2025-03-31. The company is pre-commercial and funds operations through equity raises, collaboration agreements, and grants.

Products and services

Engineered macrophage and monocyte cell therapies targeting cancer and other serious diseases. Specific pipeline asset names and clinical stage details are not supported by the provided filing excerpts.

Customers and end markets

Oncology and serious disease patient populations. No commercial customers disclosed in the provided excerpts.

Value-chain role

Clinical-stage drug developer. No manufacturing scale, commercial distribution, or downstream partnerships are confirmed by the provided excerpts.

Geographic exposure

Headquarters location and geographic operating footprint are not supported by the provided filing excerpts.

Source: SEC 10-K, filed 2025-03-31

Industry: Pharmaceutical Preparations Peers: Assembly Biosciences Inc Surrozen Inc MARIZYME, INC. HOOKIPA Pharma Inc LUMOS PHARMA, INC. Dianthus Therapeutics Inc NextCure Inc Onkure Therapeutics Inc Xilio Therapeutics Inc